


Ethics is the science of how one is under obligation without regard for any possible external lawgiving

Immanuel Kant

HIPPOCRATES (ca 460 BC - 370 BC)

Father of Clinical Medicine



*The patient, though
conscientious his
condition is perilous,
may recover his
health simply through
his contentment with
the goodness of the
physician*

Medicine and terrorism

Zbigniew Szawarski

Institute of Philosophy

Warsaw University

When Doctors Become Terrorists

Simon Wessely, M.D.

N Engl J Med 2007; 357:635-637

**Keeping one's interest in check is
the very essence of academic integrity**

Bioethical Conferences in Poland

- **Scientific integrity – 1995**
- **Scientific misconduct: an international perspective – 1998**
- **Conflict of interest and its significance in science and medicine – 2002**
- **Placebo: its action and place in health research today – 2003**
- **The ethics of intellectual property rights and patents – 2004**
- **The responsible conduct of research – 2005**
- **The Ethics of Research in Emergency Medicine – 2006**
- **The Advancement of Science and the Dilemma of Dual Use – 2007**
- **Healthcare, the market and the public's needs and interests – 2008**
- **Public Trust in Science and Industry – Supported Research and Education: Benefits and Pitfalls – 2009**
- **Workshop on Promoting Education on Dual Use Issues in the Life Sciences – 2009**

On 16 to 18 November, the U.S. National Academies of Sciences and The Polish Academy of Sciences hosted an international workshop to catalog and assess current programs on the dual use dilemma in all Nations (15).

SCIENCE VOL 326 27 NOVEMBER 2009
Published by AAAS

Online medications and their potential dual use

- the need for a transnational cooperation

Andrzej Górski

1st International Symposium on Biosecurity and Dual Use

Research of Concern

Sept 21, 2009, Rio de Janeiro

(organized by Brazilian Association for Biosecurity)

The potential dual use of online pharmacies

Letkiewicz S, Górska A.

***Sci Eng Ethics* 2009, 16, 59-75**

**INSTRUCTION
of the
MINISTER of HEALTH
of February 24, 2010**

regarding the publication by an organizational entity subordinate to or supervised by the Minister of Health of information within the scope of said entity's clinical trials on its Internet page

1. The directors of organizational entities subordinate to or supervised by the Minister of Health which function as research centers for clinical trials, hereinafter referred to as "Directors of the Entities", are instructed to publish information within the scope of clinical trials conducted by them on the organizational entity's Internet page with the goal to ensure transparency of clinical trials being conducted.
2. The information referred to in section 1 should be updated by the Directors of the Entities once a month.
3. The information referred to in section 1 shall contain:
 - 1) the title of the clinical trial
 - 2) the first and surnames, or the name or company of the sponsor, or information identifying the sponsor's representative
 - 3) information identifying the coordinator of the study or the researcher, including whether this person conducts or intends to conduct another parallel clinical trial
 - 4) the composition of the research group

- 5) the date of the begin of the clinical trial and its predicted duration
- 6) the predicted number of participants in the clinical trial and the criteria of their recruitment
- 7) information about the rights and duties of the participants in the clinical trial
- 8) the designated persons who can be contacted to obtain further information about the clinical trial and to report possible harm arising in connection with participation in the clinical trial.
- 9) the designated financial sources for the treatment of undesired events connected with participation in the clinical trial
- 10) information about the issuance of a decision by the minister of health regarding suspension of the clinical trial or rescinding permission to conduct the clinical trial or interruption of the clinical trial by the sponsor, if that be the case
- 11) information about the completion of the clinical trial if the study has been completed.

4.The information referred to in section 1 within the scope of clinical trials begun and not completed before the day of publication of this instruction shall be compiled by the Directors of the Entities and published on the Internet page of the organizational entity within 3 months of publication of this instruction.

MINISTER of HEALTH
Ewa Kopacz

DOES YOUR RESEARCH RAISE SECURITY CONCERNS? STRATEGIES FOR PROMOTING RESPONSIBLE RESEARCH IN THE LIFE SCIENCES

Sponsored by the United States Government; hosted by the National
Science Advisory Board for Biosecurity;

In partnership with the European Molecular Biology Organization, the
European Science Foundation, the European Society of Clinical
Microbiology and Infectious Diseases, and Institut Pasteur.

AGENDA:

8:00 AM Welcome and Opening Remarks

*Amy P. Patterson, M.D.
National Institutes of Health*

*Andrzej Gorski, M.D., Ph.D.
Polish Academy of Sciences*



THE NATIONAL ACADEMIES
Advisers to the Nation on Science, Engineering, and Medicine

10/18/2010

**TRENDS IN SCIENCE AND TECHNOLOGY
RELEVANT TO THE BIOLOGICAL AND TOXIN WEAPONS CONVENTION**

31 October–3 November 2010

**Institute of Biophysics
Chinese Academy of Sciences
Beijing, China**

WORKSHOP AGENDA

Sunday, 31 October

6:00 PM Reception and Welcome Remarks from Sponsoring Organizations
Best Western Olympic Stadium Hotel

Monday, 1 November

8:30 AM Meeting Registration
Institute of Biophysics

9:00 AM **Plenary Session 1:** Introduction to the Themes, Goals, and Context of the Workshop
Chair: *Andrzej Gorski, Polish Academy of Sciences*

Outline of the aims and objectives of the meeting – *Roderick Flower, Queen Mary University of London, UK*
Brief overview of Biological Weapons Convention – *Piers Millet, BWC Implementation Support Unit, Geneva*
Introduction to framework for evaluating new science and technology – *Ralf Trapp, CBW Consultant, France*
Perspective from the Chinese Academy of Sciences – *TBD, Chinese Academy of Sciences, China*
Discussion

10:30 AM *Coffee/Tea*



International BWC Workshop in Beijing, November 2010

From 4-6 November 2010, the Government of China, the Government of Canada, and the BWC Implementation Support Unit jointly hosted the international workshop "**Strengthening International Efforts to Prevent the Proliferation of Biological Weapons: The Role of the Biological and Toxin Weapons Convention**", in Beijing, China. The workshop was intended to provide an opportunity for BWC States Parties to discuss the full range of issues surrounding the BWC and its implementation, in order to prepare for the Seventh Review Conference of the BWC, which will be held in 2011.

IAP Working Group on Biosecurity

The Polish Academy of Sciences has succeeded the Royal Netherlands Academy of Arts and Sciences in the position of the Group's chair in 2010.

The current list of members: the Polish Academy of Sciences (chair), the Chinese Academy of Sciences, the Cuban Academy of Sciences, the Nigerian Academy of Sciences, the Royal Society (U.K.), and the National Academy of Sciences (U.S.). The future plans include enlarging the network of academies directly engaged in discussion on the issue of biosecurity by inviting new members to join the Group, taking into consideration equal regional distribution, while the current members will form the leadership of BWG.

IAP Statement on Biosecurity: IAP released a statement on biosecurity, endorsed by 68 members, in December 2005. The statement was presented to the UN Meeting of Experts of the Biological Weapons Convention (BWC) in Geneva. IAP members were urged to disseminate the statement to their national media.

The Working Group has also helped to organize workshops on specialized topics, including a workshop in cooperation with ICSU on trends in science and technology as an input to the 6th BWC review conference in 2006.

The latest activity of the Group was a workshop organized in cooperation with IUMS and IUBMB and held on 16-18 November 2009 in Warsaw: *Promoting Dual Use Education in the Life Sciences*. More than 60 participants from almost 30 countries took part in the event. A report *Challenges and Opportunities for Education About Dual Use Issues in the Life Sciences*, based on the Workshop findings, was officially released on 13 September 2010.



MEMBER ORGANISATION FORUM

Fostering Research Integrity in Europe

Executive Report

A report by the ESF Member Organisation Forum
on Research Integrity

integrity /in'tegri/

1 the quality of being honest and upright; uprightness:
integrity.

2 the state of being whole and undivided:
• the condition of being unbroken or complete;
• internal consistency or coherency.

(from Middle English *integer*). Compare *integument*.

www.esf.org